Israeli Stocks Lose Half a Billion Dollars Amid Mixed Wall Street Week

Last week ended with positive trends on Wall Street, led by the Nasdaq rising 3.8%, while the S&P 500 and Dow Jones gained 2.4% and 1.7%, respectively. However, several Israeli-linked stocks experienced significant declines during this period.

Checkpoint Software Technologies saw its shares drop nearly 9% over two days, wiping out approximately $1.3 billion in market value to about $13 billion. Despite beating earnings expectations for Q3, the company reported lower-than-expected revenues and issued a cautious forecast for the quarter. Analysts noted ongoing pressures from organizational changes in sales, with some expecting short-term disruption but potential growth by 2027.

Radcom shares plunged 21.1% on Thursday after the company cut its annual revenue forecast to $57-63 million, down from a previous estimate of $78.6 million. The decline followed a disappointing Q2 revenue estimate of $12 million versus an expected $19.1 million. Radcom attributed the shortfall to project delays rather than cancellations and expects to remain profitable on a non-GAAP basis. CEO Benny Epstein anticipates a return to double-digit growth in 2027.

Karyopharm Therapeutics, an American-Israeli pharmaceutical firm, suffered a 72.6% stock collapse after announcing failure in a Phase 3 clinical trial for a uterine cancer drug. The company will now focus resources on treatments for myelofibrosis and multiple myeloma. CEO Richard Paulson highlighted upcoming milestones in these areas, but the stock’s market value dropped to a historic low of $44 million. Karyopharm was founded by Israeli Dr. Sharon Shacham and maintains a development center in Israel.

Overall, these developments erased roughly half a billion dollars in market capitalization from Israeli-related stocks despite Wall Street’s broader gains, reflecting sector-specific challenges and cautious investor sentiment.